BACKGROUND: The bioactive steroid, marinobufagenin, is an endogenous Na/K-ATPase bufadienolide inhibitor that is synthesized by adrenocortical and placental cells. Marinobufagenin binding to Na/K-ATPase initiates profibrotic cell signaling, and heightened marinobufagenin levels are implicated in the pathogenesis of hypertension, preeclampsia, and chronic kidney disease. Steroids are derived from cholesterol through the traditional steroidogenesis pathway initiated by enzyme CYP11A1, and via the acidic bile acid pathway, which is controlled by enzyme CYP27A1. The mechanism of marinobufagenin biosynthesis in mammals, however, remains unknown. METHODS AND RESULTS: Here, we show that post-transcriptional silencing of the CYP27A1 gene in human trophoblast and rat adrenocortical cells reduced the expression of CYP27A1 mRNA by 70%, reduced total bile acids 2-fold, and marinobufagenin levels by 67% when compared with nontreated cells or cells transfected with nontargeting siRNA. In contrast, silencing of the CYP11A1 gene did not affect marinobufagenin production in either cell culture, but suppressed production of progesterone 2-fold in human trophoblast cells and of corticosterone by 90% in rat adrenocortical cells when compared with cells transfected with nontargeting siRNA. In vivo, in a high-salt administration experiment, male and female Dahl salt-sensitive rats became hypertensive after 4 weeks on a high-NaCl diet, their plasma marinobufagenin levels doubled, and adrenocortical CYP27A1 mRNA and protein increased 1.6-fold and 2.0-fold. CONCLUSIONS: Therefore, the endogenous steroidal Na/K-ATPase inhibitor, marinobufagenin, is synthesized in mammalian placenta and adrenal cortex from cholesterol through the novel acidic bile acid pathway. These findings will help to understand the role of marinobufagenin in highly prevalent human cardiovascular diseases.
BACKGROUND: The bioactive steroid, marinobufagenin, is an endogenous Na/K-ATPase bufadienolide inhibitor that is synthesized by adrenocortical and placental cells. Marinobufagenin binding to Na/K-ATPase initiates profibrotic cell signaling, and heightened marinobufagenin levels are implicated in the pathogenesis of hypertension, preeclampsia, and chronic kidney disease. Steroids are derived from cholesterol through the traditional steroidogenesis pathway initiated by enzyme CYP11A1, and via the acidic bile acid pathway, which is controlled by enzyme CYP27A1. The mechanism of marinobufagenin biosynthesis in mammals, however, remains unknown. METHODS AND RESULTS: Here, we show that post-transcriptional silencing of the CYP27A1 gene in human trophoblast and ratadrenocortical cells reduced the expression of CYP27A1 mRNA by 70%, reduced total bile acids 2-fold, and marinobufagenin levels by 67% when compared with nontreated cells or cells transfected with nontargeting siRNA. In contrast, silencing of the CYP11A1 gene did not affect marinobufagenin production in either cell culture, but suppressed production of progesterone 2-fold in human trophoblast cells and of corticosterone by 90% in ratadrenocortical cells when compared with cells transfected with nontargeting siRNA. In vivo, in a high-salt administration experiment, male and female Dahl salt-sensitive rats became hypertensive after 4 weeks on a high-NaCl diet, their plasma marinobufagenin levels doubled, and adrenocorticalCYP27A1 mRNA and protein increased 1.6-fold and 2.0-fold. CONCLUSIONS: Therefore, the endogenous steroidal Na/K-ATPase inhibitor, marinobufagenin, is synthesized in mammalian placenta and adrenal cortex from cholesterol through the novel acidic bile acid pathway. These findings will help to understand the role of marinobufagenin in highly prevalent humancardiovascular diseases.
Authors: Steven T Haller; David J Kennedy; Amjad Shidyak; George V Budny; Deepak Malhotra; Olga V Fedorova; Joseph I Shapiro; Alexei Y Bagrov Journal: Am J Hypertens Date: 2012-03-01 Impact factor: 2.689
Authors: A Y Bagrov; O V Fedorova; R I Dmitrieva; W N Howald; A P Hunter; E A Kuznetsova; V M Shpen Journal: Hypertension Date: 1998-05 Impact factor: 10.190
Authors: D A Lopatin; E K Ailamazian; R I Dmitrieva; V M Shpen; O V Fedorova; P A Doris; A Y Bagrov Journal: J Hypertens Date: 1999-08 Impact factor: 4.844
Authors: Erik R Nelson; Suzanne E Wardell; Jeff S Jasper; Sunghee Park; Sunil Suchindran; Matthew K Howe; Nicole J Carver; Ruchita V Pillai; Patrick M Sullivan; Varun Sondhi; Michihisa Umetani; Joseph Geradts; Donald P McDonnell Journal: Science Date: 2013-11-29 Impact factor: 47.728
Authors: Olga V Fedorova; Artem V Fadeev; Yulia N Grigorova; Courtney A Marshall; Valentina Zernetkina; Nikolai I Kolodkin; Natalia I Agalakova; Alexandra O Konradi; Edward G Lakatta; Alexei Y Bagrov Journal: J Cardiovasc Pharmacol Date: 2019-11 Impact factor: 3.105
Authors: Michél Strauss; Wayne Smith; Wen Wei; Alexei Y Bagrov; Olga V Fedorova; Aletta E Schutte Journal: J Hypertens Date: 2018-12 Impact factor: 4.844
Authors: Steven T Haller; Yanling Yan; Christopher A Drummond; Joe Xie; Jiang Tian; David J Kennedy; Victoria Y Shilova; Zijian Xie; Jiang Liu; Christopher J Cooper; Deepak Malhotra; Joseph I Shapiro; Olga V Fedorova; Alexei Y Bagrov Journal: J Am Heart Assoc Date: 2016-09-30 Impact factor: 5.501